Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Edgewise Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Edgewise Therapeutics, Inc.

EWTX

Edgewise Therapeutics, Inc.

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule therapies for severe muscle diseases, including muscular dystrophies and cardiac disorders. Its core programs target muscle damage and dysfunction through proprietary precision medicine platforms, with lead candidates like sevasemten and EDG-7500 designed to protect muscle fibers and improve function. The company aims to address unmet needs in rare neuromuscular and cardiovascular conditions worldwide.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Edgewise Therapeutics, Inc.

1
1
Edgewise Therapeutics, Inc. Edgewise Therapeutics Reports $167.8 Million Net Loss for 2025, Advances Clinical Programs

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
Edgewise Therapeutics, Inc. Edgewise Therapeutics Reports $133.8 Million Net Loss for 2024, Driven by Increased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments